LobSig: 194-Gene Predictor for Invasive Lobular Carcinoma Outcome

LobSig is a 194-gene signature derived from an integrative analysis of 303 ILC tumors to predict patient survival. The dataset supports a related manuscript and contains links to gene expression, copy number, and survival analysis data from the UQCCR, METABRIC, and TCGA cohorts. McCart Reed Amy Ellen authored the study, which used fresh frozen tumors from the Brisbane Breast Bank and the Australian Breast Cancer Tissue Bank.

Use Cases

• Training prognostic models for ILC based on the 194-gene LobSig signature mentioned in the description
• Comparing the performance of different gene expression prognostic tests (e.g., NPI, GGI, PAM50 ROR, OncotypeDx) as referenced in the description
• Analyzing correlations between DNA copy number alterations and mRNA expression for genes like FGFR1 and CCND1 as described
• Validating survival predictions in different ILC subtypes using the provided survival plots

Strengths

• Integrates data from three distinct cohorts (UQCCR, METABRIC, TCGA) totaling 303 ILC tumors
• Focuses on a specific and understudied breast cancer subtype, Invasive Lobular Carcinoma
• Derives a specific, prognostic 194-gene signature (LobSig) validated across cohorts

Limitations

• Row count and file sizes are unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• Data may reflect geographic and institutional bias inherent to the source cohorts

Provenance

Source

University of Queensland Centre for Clinical Research (UQCCR), METABRIC, TCGA, Brisbane Breast Bank, Australian Breast Cancer Tissue Bank

Collection Method

In silico integrative analysis of gene expression and DNA copy number using SNP array data from fresh frozen ILC tumors.

Geography

Likely includes data from Australia (UQCCR, Australian Breast Cancer Tissue Bank) and international cohorts (METABRIC, TCGA).